Drug Safety Oversight Initiatives Spur CDRH Postmarket Soul-Searching
This article was originally published in The Gray Sheet
Executive Summary
The recent spotlight on drug safety is prompting FDA's Center for Devices & Radiological Health to re-examine its regulatory approach to devices
You may also be interested in...
Crawford Comes Under House Democrat Fire For Postmarket Safety Lapses
FDA could seek authority to require device and drug firms to conduct postmarket safety studies, Commissioner Lester Crawford suggested July 26 during a House Appropriations/Agriculture, Rural Development & Related Agencies Subcommittee hearing
Crawford Comes Under House Democrat Fire For Postmarket Safety Lapses
FDA could seek authority to require device and drug firms to conduct postmarket safety studies, Commissioner Lester Crawford suggested July 26 during a House Appropriations/Agriculture, Rural Development & Related Agencies Subcommittee hearing
IoM Pediatric Report Calls For Congressional Action, Better Collaboration
Improving FDA postmarket surveillance capabilities will require congressional intervention in addition to other non-legislative measures, an Institute of Medicine report on pediatric device regulation issued July 18 suggests